Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: Breathing tobacco smoke can damage the heart and blood vessels of nonsmokers, too. #HeartMonth… https://t.co/Ya7tAUGY1p
SteveFDA (R-D.C.)
@SGottliebFDA
Happy #ValentinesDay! Leave the pack for good so cigarette smoke isn’t clouding out the love in the air: https://t.co/OYqh9DhA3R #healthpolicyvalentines https://t.co/loVbisbJvz
SteveFDA (R-D.C.)
@SGottliebFDA
If you’re planning treats for your four-legged pal this #ValentinesDay, make sure they’re pet-appropriate. #NoChocolate https://t.co/2cILmXZ2eI https://t.co/gHwPkg8Y9N
SteveFDA (R-D.C.)
@SGottliebFDA
RT @NBCOlympics: SHAUN WHITE IS NOT HUMAN. #BestOfUS #WinterOlympics https://t.co/r5PfUbeROr https://t.co/6MmQiSZGRh
SteveFDA (R-D.C.)
@SGottliebFDA
ICYMI: The 2018 Adult Immunization Schedule #VaccinesWork https://t.co/Ij50INdoAr
SteveFDA (R-D.C.)
@SGottliebFDA
RT @Surgeon_General: Recovery is personal. Each person's recovery journey is unique. People will choose their pathway based on their c… https://t.co/tXUPUPL35s
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: Learn more about FDA actions and research related to traumatic brain injury/concussions: https://t.co/l2T1jzv5pp https://t.co/… QT @US_FDA: FDA authorizes marketing of 1st blood test to aid in eval of concussion in adults. Most patients eval'd for concuss… https://t.co/7jTV1xbsEu)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @megtirrell: Fascinating -- FDA approves first blood test to evaluate concussion in adults; says it could rule out need for CT s… https://t.co/CfbLIpQG2t
SteveFDA (R-D.C.)
@SGottliebFDA
1/3 My remarks today about the ways FDA is getting ahead of new opioid threats and addressing those crises that are already fully manifest. https://t.co/9fizFfAnYD
SteveFDA (R-D.C.)
@SGottliebFDA
2/3Though it merits consideration through a careful, science-based process, one action that we’re examining is blister packaging of the immediate release formulations of opioid drugs. https://t.co/9fizFfAnYD
SteveFDA (R-D.C.)
@SGottliebFDA
3/3 FDA is investigating whether the abuse or misuse of gabapentinoids is increasing and, if so, what should be done to address the problem. https://t.co/9fizFfAnYD
SteveFDA (R-D.C.)
@SGottliebFDA
RT @annaedney: The FDA Commissioner with some opioid news. Agency is investigating whether people are abusing epilepsy drug gabapentin (Neu… QT @SGottliebFDA: 1/3 My remarks today about the ways FDA is getting ahead of new opioid threats and addressing those crises that are… https://t.co/pIiWVoCdbz)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @CBSHealth: It's the first blood test approved for detecting brain injuries https://t.co/FTCFgcWoj8
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: Statement from @SGottliebFDA on the efficacy of the 2017-2018 influenza vaccine: https://t.co/cbveuYKulU
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
“Gottlieb also said that a national e-prescribing system for controlled substances... could help reduce prescription drug abuse and strengthen efforts to reduce the risk of certain prescription drugs.” via @RAPSorg https://t.co/uNXdhe4DfF
SteveFDA (R-D.C.)
@SGottliebFDA
1/5 Our new Alzheimer’s guidance lays groundwork for innovative approaches to studying early disease before the onset of dementia, including strategies for trials incorporating patients with very early Alzheimer’s who haven’t yet experienced any symptoms
SteveFDA (R-D.C.)
@SGottliebFDA
2/5 Our guidance reflects the understanding of the medical community that delaying or halting Alzheimer’s disease processes that lead to symptoms is the ultimate goal of treatment at this stage. https://t.co/FvgWOYDjeJ
SteveFDA (R-D.C.)
@SGottliebFDA
3/5 We recognize the important role that scientifically valid biomarkers can play in clinical studies of very early Alzheimer’s. Objective tests and diagnostic criteria are important to ensure proper enrollment.
SteveFDA (R-D.C.)
@SGottliebFDA
RT @CDCDirector: Early estimates show that #flu vaccine was 51% effective against H3N2, among children ages 6 months- 8 years of age… https://t.co/xLvVfMAAoc
SteveFDA (R-D.C.)
@SGottliebFDA
RT @steveusdin1: FDA to hold patient meeting on opioid use disorder. This will be powerful and important. https://t.co/bp2ASUjdPV
SteveFDA (R-D.C.)
@SGottliebFDA
For our Patient Focused Drug Development meeting on opioids; we’re interested in patient views on: The impact opioid use disorder has health & well-being/daily life; experience w/ prescription & other treatments; challenges/barriers to accessing/u
SteveFDA (R-D.C.)
@SGottliebFDA
BioCentury analysis of #FDA’s new initiatives in the @POTUS budget via @steveusdin1 https://t.co/0XixgPifTD
SteveFDA (R-D.C.)
@SGottliebFDA
Adults can’t favor preserving properly regulated e-cigarettes as an alternative for smokers who quit combustible tobacco, and not at same time vigorously oppose child access to e-cigs. The industry isn’t sustainable if it leads to a whole generation of yo
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
RT @RareDiseases: Yesterday, Dr. Scott Gottlieb, Commissioner of @US_FDA released a statement on advancing development of novel new t… https://t.co/rbbWlaxqp8
SteveFDA (R-D.C.)
@SGottliebFDA
RT @CDCgov: #Whoopingcough is serious and sometimes deadly for young babies. Parents, learn more about how everyone can help pr… https://t.co/IkEaSa7tdq
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA is holding a Patient-Focused Drug Development meeting in April to allow individuals with opioid use disorder bring their voice to #FDA & the drug development process. Help make this meeting a success by signing up to participate: https://t.co/VA9
SteveFDA (R-D.C.)
@SGottliebFDA
My @KHNews interview: “There are ‘situations where you see deals cut’ in which a drugmaker will get 180-day exclusivity and then be persuaded to sit on it without ever selling the drug, essentially delaying the brand drug from facing generic competition.”
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
In 2 weeks, #FDA convenes its advisory panel to help select strains for next season’s flu vaccines; and will discuss this cell vs egg data. It takes several months to produce flu vaccines; strains for next season must be selected before current season end
SteveFDA (R-D.C.)
@SGottliebFDA
I joined HHS @SecAzar and my public health colleagues for an update on the #flu https://t.co/TvWRvdwSgP https://t.co/a82tMMlj1n
SteveFDA (R-D.C.)
@SGottliebFDA
Modern, safe and effective vaccines are one of humanity’s greatest achievements - and the commitment of @WHO @gatesfoundation @US_FDA and many others to extend these opportunities to lower income countries among our most important global public health obl QT @Health_Affairs: Modeling the impact of #vaccines on averting deaths & reducing poverty in 41 low- and middle-income countries… https://t.co/GEVYtkKcvi)
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
1/3 There are reports by certain media that some of the older antigen-based rapid flu tests are not as accurate as newer tests. This is why #FDA reclassified the older tests and established special controls that include minimum performance levels.
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
“As the overdose epidemic shifted from overprescribing of short-acting prescription opioids to cheaper and more dangerous alternatives such as illicit fentanyl... FDA is looking to the internet... to identify new problems before they spiral out of control
SteveFDA (R-D.C.)
@SGottliebFDA
RT @PharmaPinkSheet: #Alzheimers Biomarkers Gain Prominence In Drug Development Guidance https://t.co/qSeUv51xdO https://t.co/CYYauGxN7P
SteveFDA (R-D.C.)
@SGottliebFDA
RT @gavi: This flu season, @CDCgov have found children ages 6 months � to 8 years �� responded significantly better to the US… https://t.co/LIzPDz49uj
SteveFDA (R-D.C.)
@SGottliebFDA
“Although the data are limited, they do suggest that gabapentinoid abuse and misuse ‘may be growing, both [when] taken alone and in combination with opioid, benzodiazepines, or other central nervous system depressants,’ Gottlieb said https://t.co/FhDbBv1a
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FishburnSimone: If FDA gets the $400 million boost proposed in the budget, this is how it wiill spend it. By @steveusdin1 in today'… https://t.co/PR5GiP1MZ1
SteveFDA (R-D.C.)
@SGottliebFDA
RT @DrMarcSiegel: Detect concussions with a blood test? https://t.co/hKnsBDFhfV @cvpayne @Varneyco @FoxBusiness @foxnewshealth… https://t.co/RL0AAuOBIB
SteveFDA (R-D.C.)
@SGottliebFDA
Consider using less costly #generics as safe and effective alternatives to your more costly brand-name medicines. Get your questions answered here: https://t.co/mNXhzawnlc https://t.co/Db2uY3cFgK
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
We’ve updated our standards for accepting clinical data from medical device studies conducted outside U.S. for applications submitted to the #FDA to increase efficiency, protect patients, and improve data quality and integrity link: https://t.co/6EaK7skxs
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
The docket is now open for public input on #FDA’s efforts to re-evaluate and modernize #FDA’s approach to development and regulation of nicotine replacement therapy products to help smokers quit cigarettes: https://t.co/tukPliNYe2 https://t.co/DUV27zFyjX
SteveFDA (R-D.C.)
@SGottliebFDA
Advancing medicinal nicotine replacement therapies that help smokers quit is a key piece of our comprehensive approach to reduce smoking-related disease and death. #FDA’s Nicotine Steering Committee’s docket for public comment on these issues opened today
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: There are no FDA-approved uses for kratom & the agency has received concerning reports about the safety of kratom,… https://t.co/ReVp972ddd